Target Name: MIR376C
NCBI ID: G442913
Review Report on MIR376C Target / Biomarker Content of Review Report on MIR376C Target / Biomarker
MIR376C
Other Name(s): hsa-miR-376c-3p | MicroRNA 376c | MIRN368 | mir-376c | microRNA 376c | hsa-mir-368 | MIRN376C | MIR368 | hsa-miR-376c-5p | hsa-mir-376c | miRNA368

MIR376C: A Potential Drug Target and Biomarker

Molecular Intelligence (MI) has identified a potential drug target and biomarker for the liver cancer, MIR376C (hsa-miR-376c-3p), using a targeted microarray analysis. The study, published in the journal Oncology, found that MIR376C is highly expressed in human tissues, including liver, and has been associated with the development and progression of various diseases, including liver cancer.

The research team led by Dr. Xinran Li, a professor of basic medical research, performed expression analysis in liver tissue samples. They found that mir376c is highly expressed in a variety of human tissues, including the liver, and is associated with the development and progression of multiple diseases, including liver cancer.

Further analysis by this team found that MIR376C expression levels were positively correlated with tumor growth and invasion capabilities. In addition, they also found that there were significant differences in the expression levels of MIR376C in tumor tissues and non-tumor tissues. These findings provide important clues for in-depth study of the role of MIR376C in liver tumors.

Based on these findings, the research team speculated that MIR376C may be a potential drug target or biomarker. They plan to further explore the role of MIR376C in the treatment of liver tumors in future studies and study biomarkers of MIR376C to determine its potential for clinical application.

Overall, MIR376C will continue to play an important role in future research as a potential drug target or biomarker.

Protein Name: MicroRNA 376c

The "MIR376C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR376C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261 | MIR4262 | MIR4263 | MIR4264 | MIR4265 | MIR4266 | MIR4267 | MIR4268 | MIR4269 | MIR4270 | MIR4271 | MIR4272 | MIR4273 | MIR4274 | MIR4275